LONDON – The European Medicines Agency (EMA) is poised to take a significant step forward in the regulation of biosimilar drugs, with the publication of its final guideline on requirements for biosimilar monoclonal antibodies (mABs).
Read More
LONDON – The discovery of a new way to prevent cells from producing tumor necrosis factor (TNF) could one day lead to the development of more specific treatments for conditions such as rheumatoid arthritis, Crohn's disease and sepsis.
Read More
Evotec AG entered its second scientific discovery collaboration with Harvard University inside a year. The company is teaming up with Harvard scientists Andy McMahon and Ben Humphreys on an initiative called CureNephron to identify novel targets – and drugs acting on them – that have disease-modifying potential in a range of kidney indications.
Read More
LONDON – e-Therapeutics plc celebrated the start of the year with the opening of a new discovery division in Oxford, UK, and is now in the thick of preparations for four clinical trials that are all due to start in 2012.
Read More
SAN FRANCISCO – Although most of the biotech world was starting last week with a J.P. Morgan Healthcare Conference hangover, it was business as usual for the redoubtable Steve Burrill, whose life sciences venture firm, Burrill & Co., recently added Capital Fund IV to its portfolio.
Read More
SAN FRANCISCO – The global recession left the U.S. and much of the rest of the world strapped for cash, with both harsh venture and capital markets taking their toll on the biotech sector. But in China, the economic situation is "really kind of the reverse," noted Greg Scott, founder and president of ChinaBio LLC.
Read More
• CrystalGenomics Inc., of Pangyo, South Korea, raised KRW3 billion (US$2.6 million) through a private placement to the Korea Seoul Life Science Fund. KSLSF is backed by the City of Seoul and the Ministry of Knowledge Economy. CrystalGenomics has raised KRW23 billion in the past month. The funds will support three clinical programs.
Read More
